Explore

Rapid Read Rapid Read
DeepMind Releases AlphaGenome Atlas to Map All Possible Human DNA Mutations

DeepMind Releases AlphaGenome Atlas to Map All Possible Human DNA Mutations

DeepMind has launched the AlphaGenome Atlas, a comprehensive dataset providing predictions for all 9 billion possible single-letter changes in the human genome. This petabyte-sized resource is freely available for academic use and aims to guide scientists in deciphering the biological code. The Atlas includes predictions for both coding (2%) and non-coding (98%) regions of DNA, along with a catalog of over 2,500 recurrent DNA motifs. It builds upon DeepMind's previous success with AlphaFold, which predicted protein structures, and is part of a broader initiative to leverage AI for scientific and medical advancements. The Atlas also features an AlphaGenome Variant Impact (AVI) score, a single metric designed to help researchers quickly assess the potential biological effect of a genetic variant. This score has been validated against clinical genomics databases and has aided in prioritizing non-coding variants linked to conditions like severe epilepsy, as demonstrated by a team at the Broad Institute in Camb...
Trendline Trendline
Alignerr Seeks Precision Medicine Data Lead for AI Training in Healthcare

Alignerr Seeks Precision Medicine Data Lead for AI Training in Healthcare

Alignerr Seeks Precision Medicine Data Lead for AI Training in Healthcare
Trendline Trendline
Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements
Trendline Trendline
GenHealth.ai Secures $16.5 Million in Series A Funding to Expand AI Agents for Healthcare Back-Office Automation

GenHealth.ai Secures $16.5 Million in Series A Funding to Expand AI Agents for Healthcare Back-Office Automation

GenHealth.ai Secures $16.5 Million in Series A Funding to Expand AI Agents for Healthcare Back-Office Automation
Rapid Read Rapid Read
AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

An AI-generated drug candidate, rentosertib, developed by Insilico Medicine, has demonstrated potential in slowing aging and treating a chronic lung disease. The drug's molecular structure was created with the assistance of artificial intelligence. Clinical trial results, published in Nature Biotechnology, indicate that rentosertib successfully reduced biological markers associated with aging. While these findings are promising, the drug is still several years away from potential regulatory approval. It is important to note that the anti-aging effects of rentosertib have not yet been tested in healthy patients, with current research focusing on its impact on biological markers rather than direct anti-aging outcomes in a broader population. The development highlights the growing role of AI in drug discovery and its potential to accelerate the identification and creation of novel therapeutic compounds for complex conditions.
Trendline Trendline
Economist Nouriel Roubini Identifies AI, Defense, and Biotech as Key Drivers of Global Investment Boom

Economist Nouriel Roubini Identifies AI, Defense, and Biotech as Key Drivers of Global Investment Boom

Economist Nouriel Roubini Identifies AI, Defense, and Biotech as Key Drivers of Global Investment Boom
Trendline Trendline
McKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding Oncology and Biopharma Services

McKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding Oncology and Biopharma Services

McKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding Oncology and Biopharma Services
Rapid Read Rapid Read
Alzheon Publishes Peer-Reviewed Data on Oral Valiltramiprosate for Early Alzheimer's Disease

Alzheon Publishes Peer-Reviewed Data on Oral Valiltramiprosate for Early Alzheimer's Disease

Alzheon, Inc., a clinical-stage biopharmaceutical company, has announced the peer-reviewed publication of data from its Phase 3 APOLLOE4 trial and a four-year Phase 2 study in the journal *Drugs*. The publication details the effects of oral valiltramiprosate (ALZ-801) on plasma biomarkers in patients with early Alzheimer's disease (AD), particularly those who are APOE4 carriers. The studies demonstrated that valiltramiprosate achieved early and sustained reductions in key blood-based biomarkers, including plasma p-tau217 and the p-tau217/Aβ42 ratio. These reductions correlated with better cognitive, functional, and brain atrophy outcomes. According to Martin Tolar, Founder, President, and CEO of Alzheon, valiltramiprosate has shown potential to meaningfully change Alzheimer's therapy by targeting the amyloid cascade and inhibiting the formation of neurotoxic soluble amyloid oligomers. The drug maintained a favorable safety profile, with no increase in ARIA-E (amyloid-related imaging abnormalities with edem...
Trendline Trendline
RNAV8 Bio Collaborates with ARPA-H to Develop Programmable RNA Medicines

RNAV8 Bio Collaborates with ARPA-H to Develop Programmable RNA Medicines

RNAV8 Bio Collaborates with ARPA-H to Develop Programmable RNA Medicines
Trendline Trendline
RNAV8 Bio Secures ARPA-H Funding for Programmable RNA Medicines Initiative

RNAV8 Bio Secures ARPA-H Funding for Programmable RNA Medicines Initiative

RNAV8 Bio Secures ARPA-H Funding for Programmable RNA Medicines Initiative
Rapid Read Rapid Read
National Institute for Health and Care Excellence Explores Ethical AI Adoption in Public Sector

National Institute for Health and Care Excellence Explores Ethical AI Adoption in Public Sector

The National Institute for Health and Care Excellence (NICE) has collaborated with the Ada Lovelace Institute to investigate the ethical and governance implications of integrating Artificial Intelligence (AI) into its operations. NICE, an organization that provides guidance and advice on health and care technologies, partnered on a project titled 'The future of HTA with AI.' This initiative specifically focused on exploring how AI could be used within NICE's Health Technology Assessment Innovation Laboratory (HTA Lab) for processes such as evidence gathering and assessment. The research aimed to understand the governance, safeguards, and prioritization frameworks necessary for effective and legitimate AI adoption, with a broader scope to NICE as an organization. The findings indicate that public bodies, even those with significant methodological expertise, are in the nascent stages of evaluating AI's effective and legitimate use.
Rapid Read Rapid Read
UC San Francisco Researchers Utilize Google DeepMind's AlphaFold to Map Autism-Related Protein Interactions

UC San Francisco Researchers Utilize Google DeepMind's AlphaFold to Map Autism-Related Protein Interactions

Researchers at the University of California, San Francisco (UCSF) have created a molecular atlas detailing over a thousand interactions between proteins derived from genes associated with autism. This groundbreaking work, published in the journal Science, aims to clarify how gene mutations contribute to profound autism. The team, led by Nevan Krogan and Dr. Matthew State, utilized Google DeepMind's AI system, AlphaFold, to identify direct protein-to-protein contacts within lab-grown cells. This application of AI significantly accelerated the research process, allowing insights that previously took years to be gained in a matter of hours. The study involved selecting 100 proteins from high-risk autism genes, injecting them into cells, and then analyzing the additional proteins that attached to them. Subsequently, they introduced mutations found in patients with profound autism to observe the resulting changes in protein interactions, conducting these experiments in frogs and brain organoids.